Revenue ($USD) : $840,831,000
R&D spend : $419,800,000.00
Employees : 9,435
Fiscal year end : 12/31/22
CEO : Zhaohua Chang

MicroPort’s cardiac rhythm management subsidiary — MicroPort CRM — announced in May that it received FDA approval for its Alizea and Celea implantable pacemakers. Microport said its newly approved devices are the longest-lasting pacemakers for their size on the market today. They offer a volume of just 11 cc and a projected longevity of 13 years. –CN